**Supplementary Figure 1. PD-L1 expression in the TC-1 syngeneic tumor increased with PDS0101 treatment.** TC-1 tumor bearing female C57BL/6J mice were treated with PBS control (100 µl s.c) or PDS0101 (s.c., 2 weekly doses starting on day 7). Tumors were harvested and processed using the Mouse Tumor Dissociation kit (Miltenyi). Cells were stained with CD45 (clone# 30-F11) and PDL1 (clone # 10F.9G2) antibodies, and run on an Attune 4-laser flow cytometer. Data was analyzed with FlowJo, n=3/group.
Supplementary Figure 2. Infiltration of immune cells into TC-1 tumor. TC-1 tumor bearing female C57BL/6J mice were treated with PBS control (100 µl s.c.), R-DOTAP (100 µl s.c.), PDS0101 (s.c., 3 weekly doses starting on day 7), Bintrafusp alfa (250 µg, i.p., days 7, 9, and 11), and/or NHS-IL-12 (50 µg, s.c., day 7). A: Total NK in tumor. B: M1 macrophage infiltration per mg tumor. C: MDSC infiltration per mg tumor. D: Treg infiltration per mg tumor. MDSC, myeloid derived suppressor cells; NK, natural killer; Treg, regulatory T cells.